EUVIMEDAvasta EUVIMED
Open access · CC BY-NC 4.0

Diazoxide choline extended‐release tablet in people with Prader‐Willi syndrome: results from long‐term open‐label study

Jennifer L Miller, Evelien Gevers, Nicola Bridges iD, Jack A Yanovski iD, Parisa Salehi, Kathryn S Obrynba, Eric I Felner, Lynne M Bird, Ashley H Shoemaker, Moris Angulo, Merlin G Butler, David Stevenson and 12 more

Obesity · 2024-02 · 32 (2) · 252-261

DOI: 10.1002/oby.23928 ↗

At a glance

Journal article in Obesity, published online on 2023-11-02. Written by Jennifer L Miller and 23 co-authors. Institution: Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, USA. Major MEDLINE topics: Prader-Willi Syndrome. Cited 28 times so far (Crossref); 20 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Soleno Therapeutics, Intramural NIH HHS, NICHD NIH HHS.

AbstraktSubjectsBibliograafilised andmedCiteRelated studies

Abstract (original language)

Objective

This study assessed the effect of 1‐year administration of diazoxide choline extended‐release tablet (DCCR) on hyperphagia and other complications of Prader‐Willi syndrome (PWS).

Methods

The authors studied 125 participants with PWS, age ≥ 4 years, who were enrolled in the DESTINY PWS Phase 3 study and who received DCCR for up to 52 weeks in DESTINY PWS and/or its open‐label extension. The primary efficacy endpoint was Hyperphagia Questionnaire for Clinical Trials (HQ‐CT) score. Other endpoints included behavioral assessments, body composition, hormonal measures, and safety.

Results

DCCR administration resulted in significant improvements in HQ‐CT (mean [SE] −9.9 [0.77], p < 0.0001) and greater improvements in those with more severe baseline hyperphagia (HQ‐CT > 22). Improvements were seen in aggression, anxiety, and compulsivity (all p < 0.0001). There were reductions in leptin, insulin, and insulin resistance, as well as a significant increase in adiponectin (all p < 0.004). Lean body mass was increased ( p < 0.0001). Disease severity was reduced as assessed by clinician and caregiver (both p < 0.0001). Common treatment‐emergent adverse events included hypertrichosis, peripheral edema, and hyperglycemia. Adverse events infrequently resulted in discontinuation (7.2%).

Conclusions

DCCR administration to people with PWS was well tolerated and associated with broad‐ranging improvements in the syndrome. Sustained administration of DCCR has the potential to reduce disease severity and the burden of care for families.

Subjects

MeSH terms (MEDLINE)

Prader-Willi SyndromeHumansChild, PreschoolDiazoxideHyperphagiaBody CompositionInsulin

Substances

DiazoxideInsulin

Authors and institutions

  • Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, USA.
  • Queen Mary University of London, Barts Health NHS Trust-Royal London Children's Hospital, London, UK.
  • Chelsea and Westminster Hospital, London, UK.
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
  • Seattle Children's Hospital, Seattle, Washington, USA.
  • Nationwide Children's Hospital, Columbus, Ohio, USA.

ORCID profiles: Nicola Bridges, Jack A Yanovski, Neil M Cowen

Funding

  • Soleno Therapeutics
  • Intramural NIH HHS
  • NICHD NIH HHS
  • NHLBI NIH HHS

Cite

APA

Miller, J. L., Gevers, E., Bridges, N., Yanovski, J. A., Salehi, P., Obrynba, K. S., Felner, E. I., Bird, L. M., Shoemaker, A. H., Angulo, M., Butler, M. G., Stevenson, D., Goldstone, A. P., Wilding, J., Lah, M., Shaikh, M. G., Littlejohn, E., Abuzzahab, M. J., Fleischman, A., …, & C601/C602 Investigators (2024). Diazoxide choline extended‐release tablet in people with Prader‐Willi syndrome: results from long‐term open‐label study. Obesity, 32(2), 252-261. https://doi.org/10.1002/oby.23928

Vancouver

Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, et al. Diazoxide choline extended‐release tablet in people with Prader‐Willi syndrome: results from long‐term open‐label study. Obesity. 2024;32(2):252-261. doi:10.1002/oby.23928

BibTeX
@article{Miller2024,
  author = {Miller, Jennifer L and Gevers, Evelien and Bridges, Nicola and Yanovski, Jack A and Salehi, Parisa and Obrynba, Kathryn S and Felner, Eric I and Bird, Lynne M and Shoemaker, Ashley H and Angulo, Moris and Butler, Merlin G and Stevenson, David and Goldstone, Anthony P and Wilding, John and Lah, Melissa and Shaikh, M Guftar and Littlejohn, Elizabeth and Abuzzahab, M Jennifer and Fleischman, Amy and Hirano, Patricia and Yen, Kristen and Cowen, Neil M and Bhatnagar, Anish and C601/C602 Investigators, C601/C602 Investigators},
  title = {Diazoxide choline extended‐release tablet in people with Prader‐Willi syndrome: results from long‐term open‐label study},
  journal = {Obesity},
  year = {2024},
  volume = {32},
  number = {2},
  pages = {252--261},
  doi = {10.1002/oby.23928}
}
Start for free →